The VIVID-1 study: A novel methodological approach provides further evidence of efficacy of selective IL-23 inhibition in Crohn's disease.

• Tác giả: Maria Cappello, Ciro Celsa
• Ngôn ngữ: eng
• Ký hiệu phân loại: 220.404 Textual criticism and word studies
• Thông tin xuất bản: United States : Med (New York, N.Y.) , 2025
• Bộ sưu tập: NCBI
• ID: 117219

Tóm tắt

The VIVID-1 study is a phase 3 randomized controlled trial assessing the efficacy and safety of mirikizumab in moderate-to-severe active Crohn's disease.